Posts

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

on

Brand‑name drug prices keep climbing in the U.S. while falling abroad, amid push for MFN pricing: Report highlights

on

Pfizer signs up to $10.5B deal with Innovent for 12 early‑stage cancer drugs from China's biotech hub

on

Replimune to ask FDA for re‑review of melanoma drug, as agency stands by past rejections

on

Advancing Innovation: Creating More Transformative Moments

on

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

on

SciSparc Subsidiary NeuroThera Labs Gets Conditional TSX Approval for 54% CliniQuantum Acquisition

on

Sapu Nano showcases Deciparticle nanomedicine and AI‑driven oncology programs at BIO 2026

on

Friday Five: ClearNote Health sharpens pancreatic play

on

GSK's functional cure data for hepatitis B drug bepirovirsen are a major leap over standard of care

on

FDA Accepts BridgeBio’s NDA for BBP‑418 as Potential First Limb‑Girdle Muscular Dystrophy Treatment

on

AbbVie gains FDA nod for ultra‑rare blood cancer ADC from ImmunoGen deal

on

Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

on

Niowave's $75M radioisotope facility and CordenPharma–AmbioPharm deal in brief

on

Human Longevity launches newco, teams with Insilico for AI‑powered longevity research — May 28, 2026 update

on

Oura pushes deeper into healthcare services with new Ring 5 launch

on

China gene editing startup YolTech raises $70M to move CRISPR therapies forward

on

9 Companies Hiring in New Jersey - BioSpace

on

Italy probes Biogen for allegedly hindering sales of rival's MS drug

on

Kardigan readies Nasdaq IPO to back three cardio drugs – latest news summary

on

US FDA advisers to weigh updating 2026-27 COVID vaccines for XFG variant

on

From Science to Practice: Senzime Obtains FDA 510(k) Clearance for Enhanced TetraGraph System

on

Utah AI prescription pilot data strengthens case for AI‑assisted Rx tools

on

Outlook wins FDA appeal for twice‑rejected eye drug Lytenava, eyes June 2026 BLA resubmission

on

Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3

on

Kardigan files for IPO to fund late‑stage cardiovascular pipeline

on

FDA delays camizestrant breast cancer drug decision after ODAC vote against benefit-risk profile

on

Akeso's ivonescimab faces high‑stakes scrutiny at ASCO 2026 plenary with HARMONi‑6 overall survival readout in lung cancer

on

Post-Hoc Live: Jeremy Levin warns of threats to U.S. biotech

on

Kura Oncology’s encouraging cancer drug data could unlock multi‑billion‑dollar market opportunity

on

Astellas five‑year plan targets record sales and deep cost cuts through 2030

on

Rocklin Lab Releases Megascale Open Protein Stability Dataset to Advance Biomolecular AI | Recent News Summary

on

Assembly Biosciences Completes $115 Million Stock and Warrant Offering With Full Underwriters Option Exercise

on